ArticleCancers2011
Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- The Interaction of Structural Analogues of Phenothiazines in p53-Dependent Cellular Signaling Pathways.ACS omega · 2026Article
- AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling Pathways.Current issues in molecular biology · 2023Article
- Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XMolecular cancer therapeutics · 2022Article
- B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.International journal of molecular sciences · 2021Review
- Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells.Molecular medicine reports · 2020Article
- Novel Nanocomplexes Targeting STAT3 Demonstrate Promising Anti-Ovarian Cancer Effects in vivo.OncoTargets and therapy · 2020Article
- Measles virus phosphoprotein inhibits apoptosis and enhances clonogenic and migratory properties in HeLa cells.Journal of biosciences · 2019Article
- Arsenite-induced apoptosis can be attenuatedToxicology research · 2019Article
- Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma.Journal of clinical medicine research · 2016Review
- Control of Apoptosis in Treatment and Biology of Pancreatic Cancer.Journal of cellular biochemistry · 2016Review
- Synthetic aminopyrrolic receptors have apoptosis inducing activity.Chemical science · 2015Article
- Broad targeting of resistance to apoptosis in cancer.Seminars in cancer biology · 2015Review
- Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.Annals of translational medicine · 2015Article
- The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.Molecular cancer · 2013Article
- Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.Future medicinal chemistry · 2012Review
- Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic cancer (PC) has a complex etiology and displays a wide range of cellular escape pathways that allow it to resist different treatment modalities. Crucial signaling molecules that function downstream of the survival pathways, particularly at points where several of these pathways crosstalk, provide valuable targets for the development of novel anti-cancer drugs. Bcl-2 family member proteins are anti-apoptotic molecules that are known to be overexpressed in most cancers including PC. The anti-apoptotic machinery has been linked to the observed resistance developed to chemotherapy and radiation and therefore is important from the targeted drug development point of view. Over the past ten years, our group has extensively studied a series of small molecule inhibitors of Bcl-2 against PC and provide solid preclinical platform for testing such novel drugs in the clinic. This review examines the efficacy, potency, and function of several small molecule inhibitor drugs targeted to the Bcl-2 family of proteins and their preclinical progress against PC. This article further focuses on compounds that have been studied the most and also discusses the anti-cancer potential of newer class of Bcl-2 drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.